Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola a… Read more
Market Cap & Net Worth: Travere Therapeutics Inc (TVTX)
Travere Therapeutics Inc (NASDAQ:TVTX) has a market capitalization of $2.56 Billion ($2.56 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4358 globally and #2735 in its home market, demonstrating a -4.21% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Travere Therapeutics Inc's stock price $27.76 by its total outstanding shares 92241550 (92.24 Million).
Travere Therapeutics Inc Market Cap History: 2015 to 2026
Travere Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows growth from $1.78 Billion to $2.56 Billion (3.63% CAGR).
Index Memberships
Travere Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.11% | #115 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.01% | #532 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.16% | #71 of 263 |
Weight: Travere Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Travere Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Travere Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.18x
Travere Therapeutics Inc's market cap is 7.18 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.75 Billion | $133.59 Million | -$47.90 Million | 13.07x | N/A |
| 2017 | $1.94 Billion | $154.94 Million | -$59.73 Million | 12.54x | N/A |
| 2018 | $2.09 Billion | $164.25 Million | -$102.68 Million | 12.71x | N/A |
| 2019 | $1.31 Billion | $175.34 Million | -$146.43 Million | 7.47x | N/A |
| 2020 | $2.51 Billion | $198.32 Million | -$169.43 Million | 12.68x | N/A |
| 2021 | $2.86 Billion | $131.84 Million | -$180.09 Million | 21.72x | N/A |
| 2022 | $1.94 Billion | $109.46 Million | -$278.48 Million | 17.72x | N/A |
| 2023 | $829.25 Million | $145.24 Million | -$111.40 Million | 5.71x | N/A |
| 2024 | $1.61 Billion | $233.18 Million | -$321.55 Million | 6.89x | N/A |
| 2025 | $3.52 Billion | $490.73 Million | -$50.26 Million | 7.18x | N/A |
Competitor Companies of TVTX by Market Capitalization
Companies near Travere Therapeutics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Travere Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Travere Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Travere Therapeutics Inc's market cap moved from $1.78 Billion to $ 2.56 Billion, with a yearly change of 3.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.56 Billion | -27.35% |
| 2025 | $3.52 Billion | +119.35% |
| 2024 | $1.61 Billion | +93.77% |
| 2023 | $829.25 Million | -57.25% |
| 2022 | $1.94 Billion | -32.25% |
| 2021 | $2.86 Billion | +13.89% |
| 2020 | $2.51 Billion | +91.94% |
| 2019 | $1.31 Billion | -37.25% |
| 2018 | $2.09 Billion | +7.40% |
| 2017 | $1.94 Billion | +11.30% |
| 2016 | $1.75 Billion | -1.87% |
| 2015 | $1.78 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Travere Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.56 Billion USD |
| MoneyControl | $2.56 Billion USD |
| MarketWatch | $2.56 Billion USD |
| marketcap.company | $2.56 Billion USD |
| Reuters | $2.56 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.